Insider Purchases: Inside the Buy

Tag: Funanc1alPharma

Illustration of a giant Eli Lilly pill capsule spilling cash, rising stock charts, and drug bottles, symbolizing blockbuster earnings, insider buying, and growth momentum.

Elite Buys Ely: Should You Buy Lilly’s Stock Too?

Eli Lilly insiders are opening their wallets after the company crushed Q2 2025 — revenue up 38%, EPS up 92%, and blockbuster drugs Zepbound and Mounjaro fueling a raised guidance. Institutions are all-in, the pipeline is buzzing, but the valuation is sky-high. Is LLY worth chasing at $639, or is patience the better prescription?

Read entire article

Tags: Biopharma, CEO Conviction, CEO insider buying, CEO Stock Purchase, CEOBuyIn, CEOConfidence, Eli Lilly, Eli Lilly vs Novo Nordisk, Funanc1al Insider Series, Funanc1al Stocks to Watch, Funanc1alBiotech, Funanc1alEdge, Funanc1alFun, Funanc1alHumor, Funanc1alInsiderSeries, Funanc1alInsights, Funanc1alInvesting, Funanc1alPharma, Funanc1alStocks, Healthcare Stocks, High Growth Stocks, Insider Buying, Institutional Ownership, LLY, Mounjaro, Obesity Drugs, Orforglipron, Pharmaceutical Earnings, Zepbound
Bezuclastinib vial on biotech lab bench, with clinical trial data and stock chart rising in background—symbolizing COGT’s potential breakthrough

Cogent Biosciences (COGT): The Biotech with a Plan, a Billion Cells, and a Bezuclastinib

Insiders are buying, trials are working, and Cogent just raised $230M. Meet bezuclastinib—the biotech drug with a Marvel name and real potential. 🧬💥

Read entire article

Tags: Bezuclastinib, Biotech Stocks, Clinical Trials, COGT, Cole Pinnow, Fairmount Funds, Funanc1al Insider Series, Funanc1alBiotech, Funanc1alEdge, Funanc1alFinance, Funanc1alFun, Funanc1alHealth, Funanc1alHumor, Funanc1alInsiders, Funanc1alInsiderSeries, Funanc1alInvesting, Funanc1alPharma, Funanc1alStocks, GIST, Insider Buying, Speculative Plays, Systemic Mastocytosis
A playful digital illustration showund. Behind him, a rollercoaster-shaped stock chart rises, dips, and teases a reing a cartoon CEO holding a giant prescription bottle labeled

Viatris: The CEO Just Bought Shares… Should You Pop a Pill or Press "Buy"?

When a CEO personally buys over half a million dollars of stock, it’s time to pay attention. Viatris (VTRS) may be undervalued, with insider confidence, institutional backing, and a promising drug pipeline. But big losses and high debt mean it’s not risk-free. Is now the time to nibble?

Read entire article

Tags: CEO Buys, CEO insider buying, CEOBuyIn, CEOConfidence, Dividends, DividendStocks, Funanc1alHealth, Funanc1alPharma, Generics, HealthcareStocks, InsiderBuying, PharmaStocks, PipelineUpdate, stock dividends, StockBuybacks, ValueInvesting, Viatris, VTRS, VTRS Stock